HALO Halozyme Therapeutics, Inc.
HALO Halozyme Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-23 1 bull converging
POC $70.71 · VWAP $80.73 · +55.6% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, Director sold $7.2M, Oct 2–8
Coverage
1 watchlist
HALO Price Structure
Loading timeframes…
Peers
Every watchlist HALO belongs to, members best 30-day change first — HALO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $2.28 versus analyst consensus of $1.82 (+25.5%).
full note →Against street estimates
How HALO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
HALO research tape
75 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.